Recombinant Factor IX Coagulation
ApprovedSmall molecule
PfizerRecombinant Factor IX Coagulation is one of 19 small molecule programs targeting Hemophilia B. It is currently in Approved.
1
Indications
2
Total Trials
0
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
42 competitors in Hemophilia B
#DrugCompanyPhaseTrials
1IB1001
MMedexus Pharma, Inc.
Phase 3
Recombinant Factor IX Coagulation
PfizerApproved
Translarna
PPTC Therapeutics
Phase 2
BENEFIX
PfizerPhase 3
Recombinant Factor IX
BBaxalta now part of Shire
Phase 3
Rfix
PfizerPhase 3
Factor Ix
CSL BehringPhase 3
Nonacog Alfa
PfizerPhase 3
Rix-FP
CSL BehringPhase 3
Rfixfc
BBioverativ Therapeutics Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]